brivudine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| uridine derivatives used as antiviral agents and as antineoplastics | 397 | 69304-47-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
anti-herpes agent; (Z)-isomer much less active against herpes simplex virus type 1 & somewhat less active against herpes simplex virus type 2 than is the (E)-isomer; both isomers show similar activity against vaccinia virus; RN given refers to (E)-trans-isomer; structure
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.13 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pharyngeal inflammation | 84.78 | 62.05 | 13 | 649 | 669 | 63487691 |
| Labelled drug-drug interaction medication error | 74.75 | 62.05 | 19 | 643 | 13380 | 63474980 |
| Oesophagitis | 63.07 | 62.05 | 17 | 645 | 14991 | 63473369 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Labelled drug-drug interaction medication error | 155.43 | 58.95 | 40 | 858 | 27610 | 79715880 |
| Pharyngeal inflammation | 78.39 | 58.95 | 13 | 885 | 1017 | 79742473 |
| Mucosal inflammation | 71.08 | 58.95 | 28 | 870 | 75552 | 79667938 |
| Oesophagitis | 66.33 | 58.95 | 20 | 878 | 24269 | 79719221 |
| Drug interaction | 62.50 | 58.95 | 45 | 853 | 415138 | 79328352 |
| Pancytopenia | 61.31 | 58.95 | 32 | 866 | 165713 | 79577777 |
| Rash maculovesicular | 60.95 | 58.95 | 7 | 891 | 31 | 79743459 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AB15 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.2 | acidic |
| pKa2 | 13.02 | acidic |
| pKa3 | 13.7 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Thymidine kinase, cytosolic | Kinase | Ki | 7 | CHEMBL | |||||
| Thymidine kinase | Kinase | Ki | 6.62 | CHEMBL | |||||
| Thymidine kinase | Kinase | IC50 | 6.52 | CHEMBL | |||||
| Thymidine kinase | Kinase | IC50 | 4.49 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D07249 | KEGG_DRUG |
| 59161 | RXNORM |
| C0163272 | UMLSCUI |
| BVD | PDB_CHEM_ID |
| CHEMBL31634 | ChEMBL_ID |
| DB03312 | DRUGBANK_ID |
| C020235 | MESH_SUPPLEMENTAL_RECORD_UI |
| 446727 | PUBCHEM_CID |
| 6267 | INN_ID |
| 2M3055079H | UNII |
| 698049003 | SNOMEDCT_US |
| 006752 | NDDF |
Pharmaceutical products:
None